CA2125667A1 - Fluorocarbon aerosol medicaments - Google Patents

Fluorocarbon aerosol medicaments

Info

Publication number
CA2125667A1
CA2125667A1 CA 2125667 CA2125667A CA2125667A1 CA 2125667 A1 CA2125667 A1 CA 2125667A1 CA 2125667 CA2125667 CA 2125667 CA 2125667 A CA2125667 A CA 2125667A CA 2125667 A1 CA2125667 A1 CA 2125667A1
Authority
CA
Canada
Prior art keywords
salbutamol
tetrafluoroethane
formulation
propellant
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2125667
Other languages
French (fr)
Other versions
CA2125667C (en
Inventor
Rachel Ann Akehurst
Anthony James Taylor
David Andrew Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Rachel Ann Akehurst
Anthony James Taylor
David Andrew Wyatt
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2125667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919126405A external-priority patent/GB9126405D0/en
Priority claimed from GB919126378A external-priority patent/GB9126378D0/en
Priority claimed from GB929202522A external-priority patent/GB9202522D0/en
Application filed by Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt, Glaxo Group Limited filed Critical Rachel Ann Akehurst
Priority to CA002303685A priority Critical patent/CA2303685C/en
Publication of CA2125667A1 publication Critical patent/CA2125667A1/en
Application granted granted Critical
Publication of CA2125667C publication Critical patent/CA2125667C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Abstract

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which consists essentially of particulate medicament selected from the group comprising salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, said particulate medicament having a particle size of less than 100 microns; and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant and with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is in the form of a physiologically acceptable salt and that when said formulation consists of salbutamol, salbutamol sulphate or beclomethasone dipropionate isopropyl alcohol solvate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 (0.866%).
CA002125667A 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments Expired - Lifetime CA2125667C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002303685A CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9126378.0 1991-12-12
GB919126405A GB9126405D0 (en) 1991-12-12 1991-12-12 Medicaments
GB919126378A GB9126378D0 (en) 1991-12-12 1991-12-12 Medicaments
GB9126405.1 1991-12-12
GB9202522.0 1992-02-06
GB929202522A GB9202522D0 (en) 1992-02-06 1992-02-06 Medicaments
PCT/EP1992/002808 WO1993011743A1 (en) 1991-12-12 1992-12-04 Medicaments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002303685A Division CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Publications (2)

Publication Number Publication Date
CA2125667A1 true CA2125667A1 (en) 1993-06-24
CA2125667C CA2125667C (en) 2000-06-13

Family

ID=27265965

Family Applications (7)

Application Number Title Priority Date Filing Date
CA002654849A Abandoned CA2654849A1 (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002362539A Expired - Fee Related CA2362539C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002402300A Expired - Lifetime CA2402300C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002586146A Expired - Lifetime CA2586146C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002447510A Expired - Lifetime CA2447510C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002125667A Expired - Lifetime CA2125667C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002303685A Expired - Lifetime CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CA002654849A Abandoned CA2654849A1 (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002362539A Expired - Fee Related CA2362539C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002402300A Expired - Lifetime CA2402300C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002586146A Expired - Lifetime CA2586146C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments
CA002447510A Expired - Lifetime CA2447510C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002303685A Expired - Lifetime CA2303685C (en) 1991-12-12 1992-12-04 Fluorocarbon aerosol medicaments

Country Status (30)

Country Link
US (10) US5674472A (en)
EP (8) EP1066828B9 (en)
JP (2) JP3026840B2 (en)
KR (1) KR100278339B1 (en)
AP (1) AP402A (en)
AT (7) ATE373465T1 (en)
AU (1) AU663904C (en)
BG (3) BG64539B1 (en)
CA (7) CA2654849A1 (en)
CY (6) CY2134B1 (en)
CZ (1) CZ287039B6 (en)
DE (8) DE69232856T3 (en)
DK (7) DK1275375T3 (en)
ES (7) ES2319873T3 (en)
GE (1) GEP20002253B (en)
GR (1) GR3036476T3 (en)
HK (3) HK1012988A1 (en)
HU (3) HU227383B1 (en)
IL (1) IL104068A (en)
IS (1) IS1709B (en)
MX (1) MX9207205A (en)
MY (1) MY109758A (en)
NO (3) NO307864B1 (en)
NZ (1) NZ246044A (en)
OA (1) OA09926A (en)
PT (6) PT1287820E (en)
RU (2) RU2129424C1 (en)
SK (1) SK279920B6 (en)
TW (1) TW232654B (en)
WO (1) WO1993011743A1 (en)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
EP0653205B1 (en) 1991-06-10 2002-10-16 Schering Corporation Non-chloroflurocarbon aerosol formulations
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
CA2125666C (en) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
ES2079210T3 (en) * 1991-12-12 1996-01-01 Glaxo Group Ltd PHARMACEUTICAL FORMULATION OF AEROSOL.
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
DE69233319T2 (en) 1991-12-18 2005-02-17 Minnesota Mining & Manufacturing Company, St. Paul Aerosol compositions for drug suspensions
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
SK280911B6 (en) * 1992-12-09 2000-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical composition
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
WO1994022427A1 (en) * 1993-04-01 1994-10-13 Amgen Inc. Method for preparing drugs to treat dermal disorders
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PE44995A1 (en) * 1994-01-27 1995-12-18 Schering Corp MOMETASONE FUROATE FOR THE TREATMENT OF LUNG DISEASES AND RESPIRATORY TRACT
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
PL180880B1 (en) * 1995-04-14 2001-04-30 Glaxo Wellcome Inc Beclomethasone inhaler with dosis metering feature
CZ296209B6 (en) * 1995-04-14 2006-02-15 Glaxo Wellcome Inc. Inhaler and inhalation system
TR199701168T1 (en) 1995-04-14 1998-05-21 Glaxo Wellcome Inc. Metered dose inhaler for Fluticasone Propionate.
ATE373613T1 (en) 1995-04-14 2007-10-15 Smithkline Beecham Corp METHOD FOR PRODUCING A DOSAGE INHALER
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
DE19652790A1 (en) * 1996-12-18 1998-06-25 Hermes Fabrik Pharm Praeparate Pharmaceutical preparations
GB9626960D0 (en) 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
PL336464A1 (en) * 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
AU4417500A (en) 1999-04-14 2000-11-14 Glaxo Group Limited Pharmaceutical aerosol formulation
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
AU7026800A (en) * 1999-09-11 2001-04-17 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
GB2388843B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd A metered dose inhaler containing a pharmaceutical formulation of fluticasone propionate
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
ATE291898T1 (en) * 1999-12-24 2005-04-15 Glaxo Group Ltd PHARMACEUTICAL AEROSOL FORMULATION CONTAINING SALMETEROL AND FLUTICASONE
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
MXPA02001323A (en) 2000-05-10 2004-07-16 Alliance Pharma Phospholipid-based powders for drug delivery.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
NZ522672A (en) * 2000-05-23 2004-07-30 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate and preparation process thereof
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
CA2382371C (en) * 2000-07-07 2011-09-20 Baxter International Inc. Medical system, method and apparatus employing mems
AR030516A1 (en) * 2000-08-31 2003-08-20 Glaxo Group Ltd USE OF A COMBINATION OF SALMETEROL AND FLUTICASONA
FI20002177A0 (en) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj New combination for asthma therapy
FI20002216A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
FI20002215A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
EP1343550B1 (en) * 2000-12-22 2017-11-22 Glaxo Group Limited Metered dose inhaler for salmeterol xinafoate
CA2708703C (en) * 2000-12-27 2012-12-04 Alan Bruce Montgomery Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DE10104370A1 (en) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions with fewer side effects
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
BR0208012A (en) * 2001-03-20 2004-03-02 Glaxo Group Ltd Uses of at least two drugs and one hfa propellant and at least one pharmaceutical composition and inhaler packaged to treat asthma
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
WO2002096462A1 (en) * 2001-05-25 2002-12-05 Pfizer Inc. An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
ATE464880T1 (en) 2002-02-04 2010-05-15 Elan Pharma Int Ltd MEDICINAL NANOPARTICLES WITH LYSOZYME SURFACE STABILIZER
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
WO2003088961A1 (en) * 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20060076010A1 (en) * 2002-12-18 2006-04-13 King Michael L Drug delivery system with vented mouthpiece
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
SE527189C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527069C2 (en) * 2003-06-19 2005-12-13 Mederio Ag Method and apparatus for administering drug powder
SE526509C2 (en) * 2003-06-19 2005-09-27 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527200C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
SE527190C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
WO2005025506A2 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
JP5618452B2 (en) 2003-09-16 2014-11-05 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングＴａｋｅｄａ ＧｍｂＨ Use of ciclesonide for the treatment of respiratory diseases
MXPA06004331A (en) * 2003-10-20 2006-06-05 Schering Corp Pharmaceutical compositions.
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
SE0303269L (en) * 2003-12-03 2005-06-04 Microdrug Ag Medical product
SE0303570L (en) * 2003-12-03 2005-06-04 Microdrug Ag Moisture-sensitive medical product
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EA013428B1 (en) 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
PE20061162A1 (en) * 2004-12-06 2006-10-14 Smithkline Beecham Corp COMPOUNDS OLEFINIC DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANES
EP1828100A1 (en) 2004-12-17 2007-09-05 Cipla Ltd. Pharmaceutical compounds and compositions
WO2006101882A2 (en) * 2005-03-16 2006-09-28 Honeywell International Inc. Medicament delivery formulations, devices and methods
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
CA2607391A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
ES2622493T3 (en) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibiting the JAK route
DE102006017320A1 (en) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
CN104188907A (en) 2007-02-11 2014-12-10 Map药物公司 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2009088553A1 (en) 2007-10-22 2009-07-16 Board Of Regents, The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
WO2009059219A2 (en) * 2007-11-02 2009-05-07 Wayne State University Method of engineering polar drug particles with surface-trapped hydrofluoroalkane-philes
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2662046B1 (en) 2008-05-09 2023-03-15 Nuvaira, Inc. Systems and assemblies for treating a bronchial tree
PE20150621A1 (en) 2009-01-23 2015-05-07 Rigel Pharmaceuticals Inc DERIVATIVES OF 2,4-DIAMINE-PYRIMIDINE N2, N4-DISUSTITUTED AS JAK3 INHIBITORS
MX2011013061A (en) * 2009-06-05 2012-02-28 Aciex Therapeutics Inc Ophthalmic formulations of fluticasone and methods of use.
CN107049479B (en) 2009-10-27 2020-10-16 努瓦拉公司 Delivery device with coolable energy emitting assembly
KR101820542B1 (en) 2009-11-11 2018-01-19 호라이라 인코포레이티드 Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AR079451A1 (en) 2009-12-18 2012-01-25 Nycomed Gmbh COMPOUNDS 3,4,4A, 10B-TETRAHIDRO-1H-TIOPIRANO [4,3-C] ISOQUINOLINA
AU2011210352A1 (en) 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
CN102416179B (en) 2010-09-28 2014-05-07 益得生物科技股份有限公司 Inhaled compound composition for asthma
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
JP2014519519A (en) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel 3,4,4a, 10b-tetrahydro-1H-thiopyrano [4,3-c] isoquinoline compounds
AU2012269133A1 (en) 2011-06-17 2014-01-30 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
GB201118188D0 (en) * 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
CA2865504A1 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
RU2494730C1 (en) * 2012-03-27 2013-10-10 Шолекс Девелопмент Гмбх Inhalation preparation for treating respiratory diseases containing micronised salmeterol xinafoate and micronised fluticasone propionate as active substances and method for preparing it
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2016018892A1 (en) 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
WO2021026451A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
BR112022001896A2 (en) 2019-08-14 2022-06-21 Rigel Pharmaceuticals Inc Method to block or attenuate cytokine release syndrome
TW202346291A (en) 2022-03-23 2023-12-01 美商雷傑製藥公司 Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (en) * 1957-01-31 1957-04-11
BE629985A (en) † 1962-11-29
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US3895111A (en) * 1973-06-27 1975-07-15 American Cyanamid Co Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US4044125A (en) * 1975-07-18 1977-08-23 Eli Lilly And Company Method of stabilizing acetylsalicylic acid in the presence of d-propoxyphene hydrochloride and compositions thereof
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
NL7708731A (en) † 1976-08-13 1978-02-15 Montedison Spa PROCESS FOR THE PREPARATION OF NEW DRIVER COMPOSITIONS FOR AEROSOLS.
US4117958A (en) * 1976-12-27 1978-10-03 Spitzer Joseph G Vapor tap valve for aerosol containers used with flammable propellants
PH24267A (en) * 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
CY1291A (en) † 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
US4578221A (en) * 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
FI63672C (en) * 1980-05-19 1983-08-10 Orion Yhtymae Oy FOERFARANDE FOER FRAMSTAELLNING AV EN BLANDNING AV BEKLOMETASONDIPROPIONAT OCH TRIKLORFLUORMETAN ELLER DIKLORDIFLUORMETAN
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3905726A1 (en) * 1989-02-24 1990-08-30 Hoechst Ag COMPRESSED GAS PACKING AND DRIVING AGENT FOR AEROSOLS
US4940171A (en) * 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB2235627B (en) † 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Pharmaceutical compositions comprising salmeterol and fluticasone propionate
GB8921222D0 (en) † 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS
ES2071306T3 (en) * 1990-03-23 1995-06-16 Minnesota Mining & Mfg THE USE OF Soluble Fluorinated Surfactants FOR THE PREPARATION OF DOSAGE SPRAY FORMULATIONS.
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
IL98639A0 (en) * 1990-06-28 1992-07-15 Glaxo Inc Aerosol drug formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
CA2085884C (en) * 1990-06-29 2001-12-04 Asit Somani Pressurized hydrofluorocarbon aerosol compositions
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
WO1992006675A1 (en) * 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
GB9024365D0 (en) † 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) † 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
JPH04316448A (en) * 1991-04-12 1992-11-06 Iwatani Internatl Corp Production of carrot fine powder
DK0656206T3 (en) * 1991-06-10 2001-10-08 Schering Corp Aerosol formulations without chlorofluorocarbon compounds
EP0653205B1 (en) * 1991-06-10 2002-10-16 Schering Corporation Non-chloroflurocarbon aerosol formulations
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
ES2079210T3 (en) * 1991-12-12 1996-01-01 Glaxo Group Ltd PHARMACEUTICAL FORMULATION OF AEROSOL.
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
DE69233319T2 (en) * 1991-12-18 2005-02-17 Minnesota Mining & Manufacturing Company, St. Paul Aerosol compositions for drug suspensions
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
JPH0855956A (en) 1994-08-10 1996-02-27 Fuji Electric Co Ltd Drive circuit device module
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
GB9510750D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
TW382127B (en) * 1996-08-30 2000-02-11 Sony Corp Magnetic recording medium and cleaning tape
US6306396B1 (en) * 1996-10-01 2001-10-23 Corixa Corporation Compounds and methods for the diagnosis and treatment of B. microti infection
BR0208012A (en) * 2001-03-20 2004-03-02 Glaxo Group Ltd Uses of at least two drugs and one hfa propellant and at least one pharmaceutical composition and inhaler packaged to treat asthma

Also Published As

Publication number Publication date
EP1287820A1 (en) 2003-03-05
JPH07502033A (en) 1995-03-02
DE69233076T2 (en) 2004-03-18
ATE240716T1 (en) 2003-06-15
CY2566B1 (en) 2008-07-02
US5674472A (en) 1997-10-07
DK1066828T4 (en) 2007-02-26
HU211671A9 (en) 1995-12-28
IS3957A (en) 1993-06-13
DK1275375T3 (en) 2005-08-22
PT990437E (en) 2003-04-30
EP0616523B1 (en) 1998-03-04
DK0616523T3 (en) 1998-09-28
EP1275375A1 (en) 2003-01-15
WO1993011743A1 (en) 1993-06-24
PT1275375E (en) 2005-09-30
ES2199739T3 (en) 2004-03-01
CA2362539A1 (en) 1993-06-24
US5676929A (en) 1997-10-14
NO325422B1 (en) 2008-04-21
CY2493B1 (en) 2005-09-02
EP0616523A1 (en) 1994-09-28
DK1440686T3 (en) 2008-01-21
ATE296617T1 (en) 2005-06-15
CA2402300C (en) 2005-06-28
DK0756868T3 (en) 2001-09-10
CA2447510A1 (en) 1993-06-24
CA2303685C (en) 2002-02-12
ES2242823T3 (en) 2005-11-16
HK1012988A1 (en) 1999-08-13
TW232654B (en) 1994-10-21
US20030143163A1 (en) 2003-07-31
IS1709B (en) 1998-12-16
CA2586146C (en) 2009-01-20
AP9200461A0 (en) 1993-01-31
KR100278339B1 (en) 2001-01-15
ES2294386T3 (en) 2008-04-01
ES2188092T5 (en) 2009-04-01
EP1857101A3 (en) 2008-10-08
DE69224656D1 (en) 1998-04-09
JPH11310533A (en) 1999-11-09
DE69233755D1 (en) 2009-03-12
CA2303685A1 (en) 1993-06-24
ATE227975T1 (en) 2002-12-15
CA2125667C (en) 2000-06-13
DK1066828T3 (en) 2003-08-25
DE69233076D1 (en) 2003-06-26
DE69232856T2 (en) 2003-07-31
DK0990437T4 (en) 2009-02-16
DE69233712T2 (en) 2008-06-19
US20050089477A1 (en) 2005-04-28
PT1287820E (en) 2009-03-11
DE69233519T2 (en) 2006-04-27
CA2447510C (en) 2007-07-03
EP1066828B2 (en) 2006-12-06
EP0756868A2 (en) 1997-02-05
DE69233712D1 (en) 2007-10-31
CY2134B1 (en) 2002-06-21
CZ143094A3 (en) 1995-03-15
PT756868E (en) 2001-11-30
DE69231857D1 (en) 2001-07-05
NO20065102L (en) 1994-06-10
CA2654849A1 (en) 1993-06-24
DE69233519D1 (en) 2005-07-07
RU94030722A (en) 1996-10-20
EP1275375B1 (en) 2005-06-01
US6251368B1 (en) 2001-06-26
RU2179037C2 (en) 2002-02-10
US20090188491A1 (en) 2009-07-30
EP0756868B1 (en) 2001-05-30
CY2591B2 (en) 2009-11-04
AU3085092A (en) 1993-07-19
BG64539B1 (en) 2005-07-29
BG62119B1 (en) 1999-03-31
AU663904C (en) 2005-05-19
NZ246044A (en) 1996-01-26
ATE201587T1 (en) 2001-06-15
NO307864B1 (en) 2000-06-13
OA09926A (en) 1994-09-15
NO942185D0 (en) 1994-06-10
US6238647B1 (en) 2001-05-29
NO20001227L (en) 1994-06-10
DE69233076T3 (en) 2007-07-12
EP0990437B2 (en) 2008-10-22
CA2362539C (en) 2003-02-04
IL104068A (en) 1998-10-30
DK1287820T3 (en) 2009-05-18
DE69232856T3 (en) 2009-07-09
AU663904B2 (en) 1995-10-26
IL104068A0 (en) 1993-05-13
HU227681B1 (en) 2011-11-28
MX9207205A (en) 1993-11-01
GR3036476T3 (en) 2001-11-30
DE69224656T2 (en) 1998-07-23
NO942185L (en) 1994-06-10
GEP20002253B (en) 2000-10-25
ES2199739T5 (en) 2007-06-16
HUT67534A (en) 1995-04-28
HK1054500A1 (en) 2003-12-05
MY109758A (en) 1997-06-30
AP402A (en) 1995-08-22
HK1054500B (en) 2005-12-30
RU2129424C1 (en) 1999-04-27
EP1066828B9 (en) 2008-03-26
BG102689A (en) 1999-02-26
DK0990437T3 (en) 2003-03-10
DE122006000020I1 (en) 2011-12-01
DE69232856D1 (en) 2003-01-02
CA2586146A1 (en) 1993-06-24
EP0990437B1 (en) 2002-11-20
EP1857101A2 (en) 2007-11-21
US20020028183A1 (en) 2002-03-07
JP3026840B2 (en) 2000-03-27
NO20001227D0 (en) 2000-03-09
EP1440686A1 (en) 2004-07-28
ES2113444T3 (en) 1998-05-01
US20040136920A1 (en) 2004-07-15
BG98803A (en) 1995-02-28
EP1440686B1 (en) 2007-09-19
ATE163539T1 (en) 1998-03-15
ES2319873T3 (en) 2009-05-14
EP0756868A3 (en) 1997-02-26
PT1440686E (en) 2007-12-19
PT1066828E (en) 2003-10-31
HK1004711A1 (en) 1998-12-04
DE69231857T2 (en) 2001-11-29
ATE373465T1 (en) 2007-10-15
CY2441B1 (en) 2004-11-12
ES2188092T3 (en) 2003-06-16
EP0990437A1 (en) 2000-04-05
CA2402300A1 (en) 1993-06-24
HU227383B1 (en) 2011-05-30
HU0800468D0 (en) 2008-09-29
US6303103B1 (en) 2001-10-16
CZ287039B6 (en) 2000-08-16
SK279920B6 (en) 1999-05-07
ATE421315T1 (en) 2009-02-15
HU9401742D0 (en) 1994-09-28
EP1066828B1 (en) 2003-05-21
SK67494A3 (en) 1995-03-08
EP1287820B1 (en) 2009-01-21
EP1066828A1 (en) 2001-01-10
ES2158988T3 (en) 2001-09-16
CY2602B2 (en) 2010-03-03
US7498020B2 (en) 2009-03-03

Similar Documents

Publication Publication Date Title
CA2125667A1 (en) Fluorocarbon aerosol medicaments
CA2381329A1 (en) Medicaments
MY108748A (en) Medicaments
CA2125665A1 (en) Medicaments
EP0587790B1 (en) Non-chlorofluorocarbon aerosol formulations
US7601336B2 (en) Pharmaceutical aerosol composition
EP1306082B1 (en) Pressurized metered dose inhalers and pharmaceutical aerosol formulations
EP0655237A1 (en) Medicinal aerosol formulation
KR970704422A (en) Pharmaceutical composition for administration
NZ240237A (en) An aerosol formulation (free of surfactant) for treatment of asthma comprising: a hydrofluorocarbon propellant, ethanol, and beclomethasone 17,21 dipropionate; preparation thereof
HU226694B1 (en) Medicinal aerosol products containing ciclesonide
AU4260496A (en) Propellant mixture for aerosol formulation
WO1998013031A3 (en) Medicinal aerosol formulations comprising budesonide
CA2024872A1 (en) Medicaments
CA1338438C (en) Pharmaceutical composition
HUP0002533A2 (en) New combination of antiasthma medicaments
US5248493A (en) Pharmaceutical composition
WO2004103339A3 (en) Improved metered dose inhaler

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20121204